# PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

> **NCT06375109** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Chest Hospital, Capital Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Limited-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Carboplatin injection
- **DRUG:** Cisplatin injection
- **DRUG:** Etoposide injection

## Key facts

- **NCT ID:** NCT06375109
- **Lead sponsor:** Beijing Chest Hospital, Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-16
- **Primary completion:** 2027-04-15
- **Final completion:** 2029-04-15
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06375109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06375109, "PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06375109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*